Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Narendra Maharaj"'
Autor:
Shalu Kasliwal, Ranjith K., Pramod Reddy, Narendra Maharaj, Gopichand M., Aditya Adhav, Kamlesh Harsh, Nagesh Madnoorkar, Ashok Diwan, Mamraj Gupta, Ghanshyam Patel, Srinivas B. J., Mikhail Vladimirovich Dvorkin
Publikováno v:
South Asian Journal of Cancer, Vol 13, Iss 01, Pp 066-076 (2024)
Externí odkaz:
https://doaj.org/article/6c454363254749cea286cf548c7363bc
Autor:
Naveen Reddy, Pramod Reddy, Ankit Ranpura, Narendra Maharaj, Rajendersingh Arora, Gopichand Mamillapalli, Aditya Shirish Adhav, Ashok Kumar Diwan, Alexey Manikhas, Dmitriy Krasnozhon
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEDr Reddy's Laboratories Trastuzumab (DRL_TZ) is a biosimilar to Herceptin under development. The present study was conducted to evaluate efficacy, safety, pharmacokinetics (PKs), and immunogenicity of DRL_TZ in comparison with the reference me
Externí odkaz:
https://doaj.org/article/bba45b8803a44c0facf72a83a258f0a3
Autor:
Robin J. Svensson, Qing Xi Ooi, Lena E. Friberg, Narendra Maharaj, Pramod Kumar Reddy, Luis López‐Lázaro, Emma Hansson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 2, Pp 154-167 (2023)
Abstract Dr. Reddy's Laboratories rituximab (DRL_RI; Dr. Reddy's Laboratories SA, Basel, Switzerland) is under development as a rituximab biosimilar. Study RI‐01‐002 (Clinical Trials Registry ‐ India/2012/11/003129), comparing DRL_RI to the ref
Externí odkaz:
https://doaj.org/article/d9761b2646aa411991644ebe95845175
Autor:
Reena Nair, Gull Mohammad Bhat, Narendra Agrawal, Manju Sengar, Pankaj Malhotra, Soniya Nityanand, Chitra Lele, Pramod Reddy, Suresh Kankanwadi, Narendra Maharaj
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundDiffuse large B-cell lymphoma (DLBCL) is an aggressive and the most common type of non-Hodgkin lymphoma (NHL). The clinical use of rituximab has improved the treatment response and survival of patients with DLBCL. The introduction of rituxi
Externí odkaz:
https://doaj.org/article/7c982ca3bb1e4a05be9808296b5be1c6
Autor:
Robin J. Svensson, Qing Xi Ooi, Lena E. Friberg, Narendra Maharaj, Pramod Kumar Reddy, Luis López‐Lázaro, Emma Hansson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 12:154-167
Dr. Reddy's Laboratories rituximab (DRL_RI; Dr. Reddy's Laboratories SA, Basel, Switzerland) is under development as a rituximab biosimilar. Study RI-01-002 (Clinical Trials Registry - India/2012/11/003129), comparing DRL_RI to the reference medicina